Results 131 to 140 of about 320,936 (255)

Norwegian consensus guidelines for selection of neuro-oncology patients to proton therapy. [PDF]

Clin Transl Radiat Oncol
Heggebø LC, Johannessen TA, Magelssen H, Sprauten M, Blakstad H, Brekke J, Goplen D, Marienhagen K, Solheim TS, Bjorland L, Brandal P.   +10 more
europepmc   +1 more source

Population pharmacokinetic modelling of amoxicillin in human breast milk—A contribution from the ConcePTION project

British Journal of Clinical Pharmacology, EarlyView.
Aims Amoxicillin, a widely used β‐lactam antibiotic, requires improved pharmacokinetic characterization during breastfeeding. This study used a population pharmacokinetic (PopPK) approach to model amoxicillin concentrations in breast milk, identify variability sources and estimate infant exposure, applying worst‐case scenarios.
Sarah Baklouti, Virginie Rigourd, Alice Panchaud, Hedvig Nordeng, Karel Allegaert, Pieter Annaert, Miao‐Chan Huang, Anaelle Monfort, Monia Guidi, Peggy Gandia   +9 more
wiley   +1 more source

Treatment trajectories among patients with musculoskeletal disorders in Norway - a register-based cohort study over 2 years. [PDF]

Scand J Prim Health Care
Tyrdal MK, Perrier F, Røe C, Natvig B, Wahl AK, Veierød MB, Robinson HS.   +6 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Intra-familial dynamics of mental distress during the Covid-19 lockdown. [PDF]

Transl Psychiatry
Pettersen JH, Eilertsen E, Hegemann L, Hannigan LJ, Lund IO, Johannessen PM, Corfield EC, Ystrom E, Andreassen OA, Havdahl A, Brandlistuen RE, Ask H.   +11 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Correction: All-cause and cause-specific mortality in older people with and without diabetes in Norwegian home care services: a nationwide registry study. [PDF]

BMC Geriatr
Teigland T, Igland J, Blytt KM, Haltbakk J, Birkeland KI, Østbye T, Kirkevold M, Iversen MM.   +7 more
europepmc   +1 more source

Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle‐Aquitaine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The French authorities mandated the use of secure prescriptions for pregabalin on May 2021. This study aimed to evaluate the impact of this measure on pregabalin use and misuse in Nouvelle‐Aquitaine, a southwestern French region with around six million inhabitants.
Maika Munech‐Herran, Véronique Moysan, Bruno Lescarret, Clément Mathieu, Antoine Pariente, Nicolas Rousselot   +5 more
wiley   +1 more source

Author Correction: Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection. [PDF]

NPJ Vaccines
Zhou F, Vahokoski J, Bergen COVID-19 Research Group, Langeland N, Cox RJ.   +4 more
europepmc   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source